ADAG

Adagene

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 55.6%
Negative

Positive
Zacks Investment Research
16 days ago
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy
Negative
Zacks Investment Research
21 days ago
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Neutral
GlobeNewsWire
1 month ago
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene's SAFEbody technology platform to generate a masked monoclonal antibody from the company's pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target.
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Positive
Zacks Investment Research
1 month ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Neutral
GlobeNewsWire
1 month ago
Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that ADG126 will be highlighted in two oral presentations at this year's CSCO Meeting, taking place September 10-14 in Jinan, China.
Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Neutral
GlobeNewsWire
1 month ago
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Neutral
GlobeNewsWire
1 month ago
Adagene to Participate in Two Investor Conferences in September
SAN DIEGO and SUZHOU, China, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at two investor conferences in September, both taking place in New York, New York.
Adagene to Participate in Two Investor Conferences in September
Positive
Zacks Investment Research
1 month ago
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Neutral
GlobeNewsWire
2 months ago
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Muzastotug (ADG126) Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Neutral
GlobeNewsWire
3 months ago
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA